Anticoagulation Management for Veno-Venous ECMO in COVID-19 Patients: Argatroban as Rescue Therapy in Heparin-Associated Thrombocytopenia

被引:0
作者
Schiavoni, Lorenzo [1 ]
Mattei, Alessia [1 ]
Cuccarelli, Martina [1 ]
Strumia, Alessandro [1 ]
Dominici, Carmelo [2 ]
Nenna, Antonio [2 ]
Aceto, Jessica [1 ]
Palazzo, Gloria [3 ]
Pascarella, Giuseppe [1 ]
Costa, Fabio [1 ]
Cataldo, Rita [1 ]
Agro, Felice Eugenio [1 ]
Carassiti, Massimiliano [1 ]
机构
[1] Fdn Policlin Univ Campus Biomed, Unit Anesthesia & Intens Care, I-00128 Rome, Italy
[2] Fdn Policlin Univ Campus Biomed, Unit Cardiac Surg, I-00128 Rome, Italy
[3] Fdn Policlin Univ Campus Biomed, Operat Res Unit Transfus Med & Cellular Therapy, I-00128 Rome, Italy
关键词
SARS-CoV-2; ECMO; heparin; HIT; argatroban; COVID-19; extracorporeal membrane oxygenation; thrombocytopenia; EXTRACORPOREAL MEMBRANE-OXYGENATION; LIFE-SUPPORT;
D O I
10.3390/jcm13226984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: Extracorporeal membrane oxygenation (ECMO) has been widely used as a life support technique in COVID-19 acute respiratory distress syndrome (ARDS). The use of anticoagulation during ECMO support remains a topic of debate. The primary aim of this study is to demonstrate the safety and efficacy of using argatroban as an anticoagulant instead of heparin in patients with heparin-associated thrombocytopenia. Methods: 40 patients were enrolled and initially treated with unfractionated heparin for anticoagulation during ECMO, composing the UFH group. Twenty-one of these patients experienced a drop in platelet count to below 100,000 cells/mm3 and, after testing negative for IgG anti-PF4/heparin, the anticoagulation was switched to argatroban, composing the ARG group. Hemorrhagic events were recorded along with blood chemistry parameters. Results: Bleedings were significantly more frequent in the UFH group than in ARG group (58/579 days vs. 21/357 days, p = 0.041). No significant differences were observed in hemorrhagic episodes for each bleeding site, except for tracheal stoma (14 vs. 1, p = 0.011). No differences in activated partial thromboplastin time (aPTT) values were found between the two groups (aPTT 42.65 s vs. 44.70 s, p = 0.443). Linear regression analysis revealed that the platelet count on day 5 was correlated with the initial platelet count but not with the type of anticoagulant used (p = 0.001, CI 0.55, 0.69 and p = 0.078). Linear regression analysis in both groups showed a correlation between the duration of ECMO support and intensive care unit stay for the median aPTT and median platelet count. Furthermore, no major systemic thrombotic events or circuit clotting were observed in this patient cohort. Conclusions: Argatroban seems to be safe in patients with persistent heparin-associated thrombocytopenia undergoing ECMO.
引用
收藏
页数:14
相关论文
共 23 条
  • [1] Extracorporeal Membrane Oxygenation for COVID-19: Updated 2021 Guidelines from the Extracorporeal Life Support Organization
    Badulak, Jenelle
    Antonini, M. Velia
    Stead, Christine M.
    Shekerdemian, Lara
    Raman, Lakshmi
    Paden, Matthew L.
    Agerstrand, Cara
    Bartlett, Robert H.
    Barrett, Nicholas
    Combes, Alain
    Lorusso, Roberto
    Mueller, Thomas
    Ogino, Mark T.
    Peek, Giles
    Pellegrino, Vincent
    Rabie, Ahmed A.
    Salazar, Leonardo
    Schmidt, Matthieu
    Shekar, Kiran
    MacLaren, Graeme
    Brodie, Daniel
    [J]. ASAIO JOURNAL, 2021, 67 (05) : 485 - 495
  • [2] Anticoagulation strategies in patients with extracorporeal membrane oxygenation: A network meta-analysis and systematic review
    Chen, Jiale
    Chen, Guoquan
    Zhao, Wenyi
    Peng, Wenxing
    [J]. PHARMACOTHERAPY, 2023, 43 (10): : 1084 - 1093
  • [3] Cost-effectiveness of Argatroban Versus Heparin Anticoagulation in Adult Extracorporeal Membrane Oxygenation Patients
    Cho, Angelina E.
    Jerguson, Kathleen
    Peterson, Joy
    Patel, Deepa, V
    Saberi, Asif A.
    [J]. HOSPITAL PHARMACY, 2021, 56 (04) : 276 - 281
  • [4] Is Stopping Heparin Safe in Patients on Extracorporeal Membrane Oxygenation Treatment?
    Chung, Yoon Sang
    Cho, Dai Yun
    Sohn, Dong Suep
    Lee, Wang Soo
    Won, Hoyoun
    Lee, Dong Hoon
    Kang, Hyun
    Hong, Joonhwa
    [J]. ASAIO JOURNAL, 2017, 63 (01) : 32 - 36
  • [5] Superior outcomes with Argatroban for heparin-induced thrombocytopenia: a Bayesian network meta-analysis
    Colarossi, Giorgia
    Maffulli, Nicola
    Trivellas, Andromahi
    Schnoering, Heike
    Hatam, Nima
    Tingart, Markus
    Migliorini, Filippo
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2021, 43 (04) : 825 - 838
  • [6] Argatroban dosing requirements in extracorporeal life support and other critically ill populations
    Dingman, J. Spencer
    Smith, Zachary R.
    Coba, Victor E.
    Peters, Michael A.
    To, Long
    [J]. THROMBOSIS RESEARCH, 2020, 189 : 69 - 76
  • [7] ELSO, 2017, Guidelines for Cardiopulmonary Extracorporeal Life Support Extracorporeal Life Support Organization
  • [8] Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study
    Fisser, Christoph
    Winkler, Maren
    Malfertheiner, Maximilian V.
    Philipp, Alois
    Foltan, Maik
    Lunz, Dirk
    Zeman, Florian
    Maier, Lars S.
    Lubnow, Matthias
    Muller, Thomas
    [J]. CRITICAL CARE, 2021, 25 (01)
  • [9] New Anticoagulants: Focus on Venous Thromboembolism
    Gomez-Outes, Antonio
    Lecumberri, Ramon
    Pozo, Carmen
    Rocha, Eduardo
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2009, 7 (03) : 309 - 329
  • [10] Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
    Halpin, David M. G.
    Criner, Gerard J.
    Papi, Alberto
    Singh, Dave
    Anzueto, Antonio
    Martinez, Fernando J.
    Agusti, Alvar A.
    Vogelmeier, Claus F.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (01) : 24 - 36